Laboratory of Molecular Endocrinology and Neurochemistry, Sechenov Institute of Evolutionary Physiology and Biochemistry of the Russian Academy of Sciences, St. Petersburg, Russia.
Bull Exp Biol Med. 2024 Aug;177(4):559-563. doi: 10.1007/s10517-024-06223-8. Epub 2024 Sep 12.
In experiments on rats, we studied the effect of 5-day intraperitoneal (15 mg/kg/day) and oral (40 mg/kg/day) administration of compound TPY3m, a stimulator of the production of thyroid hormones by the thyroid gland developed by us, on the blood levels of thyroxine, triiodothyronine, and thyroid-stimulating hormone and on morphology of the thyroid gland. With both routes of administration, TPY3m caused a sustained moderate elevation of thyroid hormones, mainly thyroxine, with little effect on the level of thyroid-stimulating hormone. TPY3m did not reduce the stimulating effect of thyroliberin on the levels of thyroid hormones and had no damaging effect on the thyroid gland. During long-term administration, compound TPY3m stimulates the production of thyroid hormones without weakening the activity of the thyroid axis. Thus, TPY3m is a prototype of drugs for correcting thyroid hormone deficiency.
在大鼠实验中,我们研究了我们开发的甲状腺激素产生刺激物 TPY3m 的腹腔内(15mg/kg/天)和口服(40mg/kg/天)给药 5 天对甲状腺激素、三碘甲状腺原氨酸和促甲状腺激素的血液水平以及甲状腺形态的影响。通过这两种给药途径,TPY3m 引起甲状腺激素的持续适度升高,主要是甲状腺素,对促甲状腺激素水平的影响很小。TPY3m 不会降低促甲状腺素释放激素对甲状腺激素水平的刺激作用,对甲状腺也没有损害作用。在长期给药期间,化合物 TPY3m 刺激甲状腺激素的产生,而不会减弱甲状腺轴的活性。因此,TPY3m 是纠正甲状腺激素缺乏症药物的原型。